A multidisciplinary panel of oncology experts convened to review current evidence gaps, controversies, and unmet needs in the management of lung cancer, highlighting the need for prospective, head‐to‐head clinical trials.
Abstract
Recent years have seen substantial advances in lung cancer management, with therapeutic options expanding rapidly through the integration of targeted therapies, immunotherapies, antibody–drug conjugates, and novel, immune‐engaging agents. Although outcomes have improved for selected patients with non–small cell lung cancer and small cell lung cancer, the increasing number of regimens has amplified clinical complexity, with persistent evidence gaps, limited head‐to‐head comparisons, and underrepresentation of key subgroups in trials. Emerging genomic tools and novel therapeutic modalities provide opportunities to further improve patient outcomes but also add to the challenges of clinical decision‐making. To address these issues, a multidisciplinary panel of oncology experts, primarily based in the United States, convened to review current evidence gaps, controversies, and unmet needs in the management of lung cancer. Key areas were identified in treatment selection and sequencing as well as the management of high‐risk subtypes, highlighting the need for prospective, head‐to‐head clinical trials. Findings from this panel will inform a 2026 follow‐up conference in which a modified Delphi method will be used to develop formal consensus recommendations to provide actionable guidance for practicing clinicians.
This review encapsulates significant developments in molecularly targeted agents and immune checkpoint inhibitors, emphasising their clinical efficacy, resistance mechanisms, and innovative therapeutic combinations, and reviews pivotal clinical trials and newly filed patents.
K. C. Geervani, R. Maddileti, Kalpi Sania Kausar et al.· Current Drug Discovery Techn...· 0 citations
Rare cancers represent a substantial health burden, comprising 25% of cancer mortality. Early-phase oncology trials are essential for rare cancers, where limited patient numbers, biological heterogeneity, and the absence of established standards of care necessitate innovative approaches to drug development. Advances in...
Y. Myat, K. Thein, Lujain Mahmood et al.· Cancers· 0 citations
This comprehensive review explores advancements in the treatment of Triple-Negative Breast Cancer, emphasizing the transformative impact of targeted therapies and immunotherapies and envisions a future where targeted and immune-based interventions redefine TNBC treatment, offering new hope for patients and clinicians a...
Gowhar Rashid, D. Elsori, Zainab Naqvi et al.· Frontiers in Oncology· 0 citations
This Systematic review provides a comprehensive framework for understanding current therapeutic options and future directions in prostate cancer treatment. It highlights ongoing efforts, focusing on AR signaling inhibitors (ARSi) and novel molecularly targeted therapies. Using PRISMA-ScR guidelines, we conducted a comp...
Syeda Ayesha Fatima, K. Haider, Sara Qutubuddin et al.· Journal of chemotherapy· 1 citation
The concept of personalized medicine has tremendous appeal—tailoring diagnosis and treatment to an individual, rather than a “one-size-fits-all” approach. The management of non-small-cell lung cancer (NSCLC) has rapidly evolved toward strategies increasingly guided by tumor biology and precision oncology. The safety an...
Emily P. Rabinovich, Linda W. Martin· Journal of Clinical Medicine· 0 citations
The identification of new molecular targets and the growth of personalized therapies for cancer depend on current studies, and it is believed that new advances in molecular science will contribute to the development of innovative and successful methods for therapy, and eventually decrease the prevalence of malignancies...
Hardha Balachandran, Gowramma Byran, S. Murugesan et al.· Current Cancer Drug Targets· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.